Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 [blinatumomab] in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL).

Next Previous
X
Search
Trial Profile

An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 [blinatumomab] in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 02 Nov 2019 Results published in the Clinical Pharmacokinetics
    • 06 Dec 2016 Results assessing Blinatumomab associated Neurologic Events in NCT00274742, NCT00560794, NCT01209286, NCT01471782, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Jun 2016 Results of the QSP model accessing MoA of blinatumomab presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top